SanBio Company Limited
Notice on domestic integration of Aculogo production framework following the closure of SunBio’s U.S. plant
In response to Acugo® production being partly shouldered by Minaris’ U.S. plant closure, upstream processes are migrated to the domestic Yokohama plant to establish an integrated manufacturing system. Diversification is pursued to stabilize supply and prepare for future U.S. expansion and adaptation. No impact on current-period results.
Key Figures
- Strengthening of upstream production framework through domestic integration of Acugo® (migration of upstream processes to Yokohama Plant)
- Migration plan due to Minaris’ U.S. plant closure
- Stabilization of supply through diversification with JCR Pharma
AI要約
Overview
SunBio plans to close Minaris’ U.S. Mountain View plant, which partly manufactures Acugo®, and migrate upstream processes to SunBio Japan Minaris Yokohama Plant to build an integrated domestic manufacturing system. This is expected to enhance manufacturing management unity, stabilize supply, and improve efficiency. Domestic inventories are already secured, and there is no expected supply disruption during the migration. In addition, we will advance diversification through a manufacturing outsourcing agreement with JCR Pharma Corporation to strengthen a stable supply framework.
Impact and Outlook
The domestic integration aims to avoid short-term supply disruption while enhancing production capacity to support future U.S. expansion and expansion of brain infarction indications. When disclosed, further information will be provided promptly. FX information is disclosed, but specific financial impact data are not provided in the text.
SanBio Company Limited
Company overview · Stock price · Financial data · All IR
